Landmark trials in endocrine adjuvant therapy for breast carcinoma

Authors

  • William Gradishar M.D.

    Corresponding author
    1. Feinberg School of Medicine, Northwestern University, Chicago, Illinois
    • Feinberg School of Medicine, Northwestern University, 676 North St. Clair St., Suite 850, Chicago, IL 60611
    Search for more papers by this author
    • Fax: (312) 695-6189

    • Dr. Gradishar has served as a consultant to AstraZeneca, Novartis, and Pfizer.


Abstract

The review summarizes the outcomes of several landmark trials involving aromatase inhibitors that helped formulate current therapeutic approaches recommended by the American Society of Clinical Oncology for breast carcinoma treatment. Cancer 2006. © 2006 American Cancer Society.

Ancillary